Sinopharm Group Co (SHTDY) AI Stock Analysis

• Market Cap: $7.23B
• Dividend Yield: 4.26%
• Average Volume (3M): 1.07K
• Price to Earnings (P/E): 7.4
• Beta (1Y): 0.33
• Revenue Growth: -3.62%
• EPS Growth: -23.24%
• Country: US
• Employees: 108,217
• Sector: Healthcare
• Sector Strength: 60
• Industry: Medical - Distribution
• EPS (TTM): 1.57
• Shares Outstanding: 268,362,150
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 1,069
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Sinopharm Group's overall score is driven by its solid financial performance and attractive valuation. While the company shows stability in revenue and profitability, the slight decline in revenue growth and free cash flow are areas of concern. The technical analysis suggests caution, as the stock trades below key moving averages, indicating potential downward pressure. However, the low P/E ratio and high dividend yield present a potentially undervalued investment opportunity.

Sinopharm Group Co Business Overview & Revenue Model

Company Description

Sinopharm Group Co., Ltd. (SHTDY) is a leading healthcare company based in China, operating primarily in the pharmaceutical distribution, pharmaceutical retail, and medical device sectors. As a comprehensive healthcare service provider, Sinopharm distributes a wide range of pharmaceutical products, traditional Chinese medicines, medical devices, and healthcare products. The company also operates a large network of retail pharmacies and is involved in the research and development of new drugs and medical technologies.

How the Company Makes Money

Sinopharm Group Co., Ltd. generates revenue through multiple streams, with the primary source being the distribution of pharmaceuticals and medical devices. The company leverages its extensive distribution network to supply hospitals, clinics, and pharmacies across China, ensuring a steady flow of income from wholesale operations. Additionally, Sinopharm operates a chain of retail pharmacies, which contributes to its revenue by directly selling medicines and healthcare products to consumers. The company also benefits from its involvement in the research and development sector, where it develops and licenses new pharmaceutical products. Strategic partnerships and collaborations with domestic and international pharmaceutical companies further enhance its market reach and revenue potential.

Sinopharm Group Co Financial Statement Overview

Summary

Sinopharm Group Co exhibits strong financial health with consistent revenue and profit growth, a stable balance sheet, and effective cash flow management. However, attention to debt management is advised to maintain financial stability.

Income Statement

Sinopharm Group Co has demonstrated consistent revenue growth, with a notable increase in total revenue from 2019 to 2023. The gross profit margin has remained stable, showcasing effective cost management. However, the EBIT margin shows slight fluctuations, indicating potential operational challenges. The net profit margin reflects a stable profitability, but there's room for improvement.

Balance Sheet

The company's balance sheet is strong with a healthy equity ratio, indicating financial stability. The debt-to-equity ratio is moderate, reflecting a balanced approach to leverage. Return on equity has improved over the years, showing effective utilization of equity resources. However, the increasing total debt requires careful monitoring to avoid potential risks.

Cash Flow

Sinopharm Group has shown a positive trend in operating cash flow, which supports net income, indicating good cash generation from operations. The free cash flow growth rate has been positive, reflecting strong cash management. However, fluctuations in free cash flow to net income ratio suggest variability in cash flow efficiency.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
596.57B	552.15B	521.05B	456.41B	425.27B
	Gross Profit
48.51B	47.43B	44.05B	40.32B	37.53B
	EBIT
20.21B	20.60B	19.71B	17.76B	16.14B
	EBITDA
26.90B	26.25B	24.68B	22.62B	20.32B
	Net Income Common Stockholders
9.05B	8.53B	7.76B	7.19B	6.25B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
63.81B	55.22B	43.54B	50.22B	39.19B
	Total Assets
383.39B	364.78B	335.41B	311.24B	269.89B
	Total Debt
73.78B	69.59B	68.37B	68.53B	55.14B
	Net Debt
9.97B	14.37B	24.84B	18.35B	15.95B
	Total Liabilities
263.08B	254.71B	235.76B	221.29B	192.95B
	Stockholders Equity
74.58B	68.07B	61.89B	56.36B	47.42B
Cash Flow		Free Cash Flow
14.84B	18.55B	7.05B	9.07B	16.23B
	Operating Cash Flow
17.17B	20.96B	9.31B	11.15B	18.78B
	Investing Cash Flow
-944.53M	-3.59B	-1.27B	-2.20B	-6.80B
	Financing Cash Flow
-7.64B	-5.69B	-14.69B	2.03B	-13.08B

Sinopharm Group Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Negative. The current price of 11.59 is above the 20-day moving average (MA) of 11.53, below the 50-day MA of 12.06, and below the 200-day MA of 12.55, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 46.51 is Neutral, neither overbought nor oversold. The STOCH value of 78.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SHTDY.

Sinopharm Group Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MCK	77 Outperform	$88.78B	32.47	51.23%	0.39%	14.29%	-1.20%
SHTDY	75 Outperform	$7.23B	7.38	9.19%	4.26%	-3.62%	-23.24%
COR	73 Outperform	$56.65B	41.56	245.32%	0.72%	11.64%	-23.54%
HSIC	72 Outperform	$8.00B	21.81	11.78%	―	2.71%	-3.26%
CAH	68 Neutral	$35.69B	23.35	-43.80%	1.35%	0.78%	183.45%
Sector *	52 Neutral	$5.35B	3.83	-41.70%	2.85%	17.03%	1.22%